BZ Fine Pharma

Reference Data

ISIN LU0695504364
Valor Number 14142705
Bloomberg Global ID
Fund Name BZ Fine Pharma
Fund Provider BZ Bank Aktiengesellschaft Wilen, Switzerland
Phone: +41 44 786 66 00
Web: www.bzbank.ch
Fund Provider BZ Bank Aktiengesellschaft
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) BZ Bank Aktiengesellschaft
Wilen b. Wollerau
Phone: +41 44 786 61 11
Asset Class Equities
EFC Category Equity Health Care
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund does not charge any issuing commission and/or fees (units are issued at the NAV)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The objective of the investment policy for the fund is to achieve appropriate growth in the respective unit class currency taking account of the investment risk. The total yield of the sub-fund must not only contain the whole of the invested capital but must also be at least equal to inflation and produce an attractive actual yield. The yield should considerably exceed that of fixed-interest and real estate investments.
Peculiarities

Fund Prices

Current Price * 212.83 CHF 04.06.2025
Previous Price * 211.68 CHF 03.06.2025
52 Week High * 262.13 CHF 03.09.2024
52 Week Low * 201.85 CHF 22.04.2025
NAV * 212.83 CHF 04.06.2025
Issue Price * 217.08 CHF 04.06.2025
Redemption Price * 208.57 CHF 04.06.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 37,541,642
Unit/Share Assets *** 23,087,011
Trading Information SIX

Performance

YTD Performance -10.08% 30.12.2024
04.06.2025
1 month -2.23% 05.05.2025
04.06.2025
3 months -15.72% 04.03.2025
04.06.2025
6 months -12.73% 04.12.2024
04.06.2025
1 year -14.22% 04.06.2024
04.06.2025
2 years -9.56% 05.06.2023
04.06.2025
3 years -7.15% 07.06.2022
04.06.2025
5 years -22.87% 04.06.2020
04.06.2025

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Vertex Pharmaceuticals Inc 5.89%
McKesson Corp 5.87%
Eli Lilly and Co 5.65%
Novartis AG Registered Shares 5.59%
Roche Holding AG 5.55%
AstraZeneca PLC 5.45%
AbbVie Inc 5.15%
Sanofi SA 5.02%
Swedish Orphan Biovitrum AB 4.52%
Genmab AS 4.46%
Last data update 30.04.2025

Cost / Risk

TER
TER date
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.58%
SRRI ***
SRRI date *** 31.05.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)